Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization - Total (2016 - 2019)

Amicus Therapeutics' Depreciation & Amortization - Total history spans 6 years, with the latest figure at $991000.0 for Q1 2019.

  • For the quarter ending Q1 2019, Depreciation & Amortization - Total rose 2.27% year-over-year to $991000.0, compared with a TTM value of $991000.0 through Dec 2019, down 76.4%, and an annual FY2025 reading of $3.9 million, down 22.0% over the prior year.
  • Depreciation & Amortization - Total for Q1 2019 was $991000.0 at Amicus Therapeutics, down from $1.2 million in the prior quarter.
  • The five-year high for Depreciation & Amortization - Total was $1.2 million in Q4 2018, with the low at $353000.0 in Q2 2015.
  • Average Depreciation & Amortization - Total over 5 years is $830562.5, with a median of $873500.0 recorded in 2016.
  • Year-over-year, Depreciation & Amortization - Total fell 10.86% in 2015 and then soared 126.84% in 2016.
  • Tracing FOLD's Depreciation & Amortization - Total over 5 years: stood at $395000.0 in 2015, then skyrocketed by 129.37% to $906000.0 in 2016, then increased by 22.96% to $1.1 million in 2017, then grew by 6.37% to $1.2 million in 2018, then dropped by 16.37% to $991000.0 in 2019.
  • Per Business Quant, the three most recent readings for FOLD's Depreciation & Amortization - Total are $991000.0 (Q1 2019), $1.2 million (Q4 2018), and $1.1 million (Q3 2018).